|
| 37425870 | Uncovering Protein Ensembles: Automated Multiconformer Model Building for X-ray Crystallography and Cryo-EM. | bioRxiv | 2024 |
| 37205593 | Refinement of Multiconformer Ensemble Models from Multi-temperature X-ray Diffraction Data. | bioRxiv | 2023 |
| 37748828 | Refinement of multiconformer ensemble models from multi-temperature X-ray diffraction data. | Methods Enzymol | 2023 |
| 35312477 | Ligand binding remodels protein side-chain conformational heterogeneity. | Elife | 2022 |
| 36177448 | A patient-driven clinicogenomic partnership for metastatic prostate cancer. | Cell Genom | 2022 |
| 33210433 | qFit 3: Protein and ligand multiconformer modeling for X-ray crystallographic and single-particle cryo-EM density maps. | Protein Sci | 2021 |
| 33542514 | Cryo-EM model validation recommendations based on outcomes of the 2019 EMDataResource challenge. | Nat Methods | 2021 |
| 34496240 | Molecular features of exceptional response to neoadjuvant anti-androgen therapy in high-risk localized prostate cancer. | Cell Rep | 2021 |
| 32353859 | A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. | Nature | 2020 |
| 32786289 | Robust Sequence Determinants of α-Synuclein Toxicity in Yeast Implicate Membrane Binding. | ACS Chem Biol | 2020 |
| 32868381 | Genomic Predictors of Good Outcome, Recurrence, or Progression in High-Grade T1 Non-Muscle-Invasive Bladder Cancer. | Cancer Res | 2020 |
| 31152158 | Publisher Correction: The long tail of oncogenic drivers in prostate cancer. | Nat Genet | 2019 |
| 31747605 | CREB5 Promotes Resistance to Androgen-Receptor Antagonists and Androgen Deprivation in Prostate Cancer. | Cell Rep | 2019 |
| 31253631 | Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer. | Clin Cancer Res | 2019 |
| 29301960 | Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. | Science | 2018 |
| 29909985 | Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing. | Cell | 2018 |
| 29859727 | Commentary on "DNA damage response and repair gene alterations are associated with improved survival in patients with platinum-treated advanced urothelial carcinoma." | Urol Oncol | 2018 |
| 30150660 | Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. | Nat Genet | 2018 |
| 30179225 | Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. | J Clin Invest | 2018 |
| 30139659 | Racial disparity in quality of care and overall survival among black vs. white patients with muscle-invasive bladder cancer treated with radical cystectomy: A national cancer database analysis. | Urol Oncol | 2018 |
| 30220708 | Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma. | Br J Cancer | 2018 |
| 30382943 | Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. | J Clin Invest | 2018 |
| 29674707 | Targeted genomic landscape of metastases compared to primary tumours in clear cell metastatic renal cell carcinoma. | Br J Cancer | 2018 |
| 29610475 | The long tail of oncogenic drivers in prostate cancer. | Nat Genet | 2018 |
| 29748390 | The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma. | Cancer Immunol Res | 2018 |
| 29706503 | Nomogram to Assess the Survival Benefit of New Salvage Agents for Metastatic Urothelial Carcinoma in the Era of Immunotherapy. | Clin Genitourin Cancer | 2018 |
| 27700015 | Outcomes in patients with advanced urothelial carcinoma after discontinuation of programmed death (PD)-1 or PD ligand 1 inhibitor therapy. | BJU Int | 2017 |
| 32913968 | Genomic Resistance Patterns to Second-Generation Androgen Blockade in Paired Tumor Biopsies of Metastatic Castration-Resistant Prostate Cancer. | JCO Precis Oncol | 2017 |
| 28487100 | Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications. | J Urol | 2017 |
| 28137924 | DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma. | Clin Cancer Res | 2017 |
| 29259186 | Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer. | Nat Commun | 2017 |
| 28515055 | Exome Sequencing of African-American Prostate Cancer Reveals Loss-of-Function <i>ERF</i> Mutations. | Cancer Discov | 2017 |
| 28743155 | Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology. | Cancer | 2017 |
| 28864222 | Upper Tract Urothelial Carcinomas: Prognostic Factors and Outcomes in Patients With Non-Lymph Node Distant Metastasis. | Clin Genitourin Cancer | 2017 |
| 27111282 | Chromatin immunoprecipitation from fixed clinical tissues reveals tumor-specific enhancer profiles. | Nat Med | 2016 |
| 26264159 | Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma. | Eur Urol | 2016 |
| 27584023 | Cancer immunotherapy: new applications in urologic oncology. | Curr Opin Urol | 2016 |
| 27806880 | Letter to the Editor, Re: van der Heijden AG, Mengual L, Lozano JJ, Ingelmo-Torres M, Ribal MJ, Fernández PL, Oosterwijk E, Schalken JA, Alcaraz A, Witjes JA. A five-gene expression signature to predict progression in T1G3 bladder cancer. Eur J Cancer. 2016; 64:127-136. | Eur J Cancer | 2016 |
| 27262369 | Impact of Prior Platinum-Based Therapy on Patients Receiving Salvage Systemic Treatment for Advanced Urothelial Carcinoma. | Clin Genitourin Cancer | 2016 |
| 27351382 | Association of tumour microRNA profiling with outcomes in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy. | Br J Cancer | 2016 |
| 27283319 | Correlation of Apobec Mrna Expression with overall Survival and pd-l1 Expression in Urothelial Carcinoma. | Sci Rep | 2016 |
| 26778300 | Expression Levels of DNA Damage Repair Proteins Are Associated With Overall Survival in Platinum-Treated Advanced Urothelial Carcinoma. | Clin Genitourin Cancer | 2016 |
| 26909474 | Precision medicine for advanced prostate cancer. | Curr Opin Urol | 2016 |
| 26852077 | Re: John P. Sfakianos, Eugene K. Cha, Gopa Iyer, et al. Genomic Characterization of Upper Tract Urothelial Carcinoma. Eur Urol 2015;68:970-7. | Eur Urol | 2016 |
| 25535728 | Reexamining treatment of high-grade T1 bladder cancer according to depth of lamina propria invasion: a prospective trial of 200 patients. | Br J Cancer | 2015 |
| 26320810 | Temporal trends in receipt of adequate lymphadenectomy in bladder cancer 1988 to 2010. | Urol Oncol | 2015 |
| 26039708 | Somatic Copy Number Abnormalities and Mutations in PI3K/AKT/mTOR Pathway Have Prognostic Significance for Overall Survival in Platinum Treated Locally Advanced or Metastatic Urothelial Tumors. | PLoS One | 2015 |
| 25836936 | Perioperative therapy for muscle invasive bladder cancer. | Hematol Oncol Clin North Am | 2015 |
| 25720673 | HER2 as a target in invasive urothelial carcinoma. | Cancer Med | 2015 |
| 25481485 | Incomplete Cross-Resistance Between Taxanes for Advanced Urothelial Carcinoma: Implications for Clinical Practice and Trial Design. | Clin Genitourin Cancer | 2015 |